Back to search

Peptide record

TPDB11144

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11144
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP pep-lab Peptipedia AntiCP 2.0 iACP-DRLF AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 29-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RGLRRLGRKIAHGVKKYGPTVLRIIRIAG
Physicochemical Analysis
C146H260N52O32
NDCEQMFSW
R
3256.00
12.71
10
0
12
+9
5.37
-0.210
121.03
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
45.76
2
Residue Composition
number
2
A
6
R
0
N
0
D
0
C
0
E
0
Q
5
G
1
H
4
I
3
L
3
K
0
M
0
F
1
P
0
S
1
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 2 R: 6 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 5 H: 1 I: 4 L: 3 K: 3 M: 0 F: 0 P: 1 S: 0 T: 1 W: 0 Y: 1 V: 2
Chemical Descriptors
29
C146H260N52O32
3256.00
12.71
+9
5.37
-0.210
Evidence Records 40 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.12-0.25 µM

Target

Escherichia coli ATCC 25922 or ML-35 or D21

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2
Evidence 2 Activity

Activity

MIC
Antibacterial
0.25 µM

Target

S. enterica serovar typhimurium ATCC 14028

Source & Reference

dbAMP DRAMP

Other

Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 81
Evidence 3 Activity

Activity

MIC
Antibacterial
0.25-2.0 µM

Target

Pseudomonas aeruginosa ATCC 27853 or 2 clinical isolates

Source & Reference

dbAMP DRAMP

Other

L-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC
Evidence 4 Activity

Activity

MIC
Antibacterial
0.25 µM

Target

S. marcescens ATCC 8100

Source & Reference

dbAMP DRAMP

Other

C 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate
Evidence 5 Activity

Activity

MIC
Antibacterial
0.5-1.0 µM

Target

Staphylococcus aureus ATCC 25923 or Cowan 1 MRSA clinical isolate

Source & Reference

dbAMP DRAMP

Other

C 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate
Evidence 6 Activity

Activity

MIC
Antibacterial
0.25 µM

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP DRAMP

Other

3315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25
Evidence 7 Activity

Activity

MIC
Antibacterial
1 µM

Target

Enterococcus faecalis ATCC 29212 or VREF clinical isolate

Source & Reference

dbAMP DRAMP

Other

Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans
Evidence 8 Activity

Activity

MIC
Antibacterial
0.25 µM

Target

B. megaterium Bm11

Source & Reference

dbAMP DRAMP

Other

dis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM),
Evidence 9 Activity

Activity

MIC
Antibacterial
4 µM

Target

Candida albicans clinical isolate

Source & Reference

dbAMP DRAMP

Other

aecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et
Evidence 10 Activity

Activity

MIC
Antibacterial
1.0 µM

Target

C. neoformans 3 clinical isolates

Source & Reference

dbAMP DRAMP

Other

te (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC
Evidence 11 Activity

Activity

MIC
Antibacterial
0.5 µM

Target

R. rubra

Source & Reference

dbAMP DRAMP

Other

albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2
Evidence 12 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

B. anthracis

Source & Reference

dbAMP DRAMP

Other

lates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2018 ). Antibiofilm:bacteria: inhibited bacterial biofilm:S. maltophilia
Evidence 13 Activity

Activity

MIC
Antifungal
0.12-0.25 µM

Target

Escherichia coli ATCC 25922 or ML-35 or D21

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2
Evidence 14 Activity

Activity

MIC
Antifungal
0.25 µM

Target

S. enterica serovar typhimurium ATCC 14028

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 81
Evidence 15 Activity

Activity

MIC
Antifungal
0.25-2.0 µM

Target

Pseudomonas aeruginosa ATCC 27853 or 2 clinical isolates

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

L-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC
Evidence 16 Activity

Activity

MIC
Antifungal
0.25 µM

Target

S. marcescens ATCC 8100

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

C 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate
Evidence 17 Activity

Activity

MIC
Antifungal
0.5-1.0 µM

Target

Staphylococcus aureus ATCC 25923 or Cowan 1 MRSA clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

C 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate
Evidence 18 Activity

Activity

MIC
Antifungal
0.25 µM

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

3315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25
Evidence 19 Activity

Activity

MIC
Antifungal
1 µM

Target

Enterococcus faecalis ATCC 29212 or VREF clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans
Evidence 20 Activity

Activity

MIC
Antifungal
0.25 µM

Target

B. megaterium Bm11

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

dis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM),
Evidence 21 Activity

Activity

MIC
Antifungal
4 µM

Target

Candida albicans clinical isolate

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

aecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et
Evidence 22 Activity

Activity

MIC
Antifungal
1.0 µM

Target

C. neoformans 3 clinical isolates

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

te (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC
Evidence 23 Activity

Activity

MIC
Antifungal
0.5 µM

Target

R. rubra

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2
Evidence 24 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

B. anthracis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

lates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2018 ). Antibiofilm:bacteria: inhibited bacterial biofilm:S. maltophilia
Evidence 25 Activity

Activity

MIC
Antiparasitic
0.12-0.25 µM

Target

Escherichia coli ATCC 25922 or ML-35 or D21

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2
Evidence 26 Activity

Activity

MIC
Antiparasitic
0.25 µM

Target

S. enterica serovar typhimurium ATCC 14028

Source & Reference

DRAMP

Other

Active against E. coli ATCC 25922 or ML-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 81
Evidence 27 Activity

Activity

MIC
Antiparasitic
0.25-2.0 µM

Target

Pseudomonas aeruginosa ATCC 27853 or 2 clinical isolates

Source & Reference

DRAMP

Other

L-35 or D21 (MIC 0.12-0.25 uM), S. enterica serovar typhimurium ATCC 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC
Evidence 28 Activity

Activity

MIC
Antiparasitic
0.25 µM

Target

S. marcescens ATCC 8100

Source & Reference

DRAMP

Other

C 14028 (MIC 0.25 uM), P. aeruginosa ATCC 27853 or 2 clinical isolates (MIC 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate
Evidence 29 Activity

Activity

MIC
Antiparasitic
0.5-1.0 µM

Target

Staphylococcus aureus ATCC 25923 or Cowan 1 MRSA clinical isolate

Source & Reference

DRAMP

Other

C 0.25-2.0 uM), S. marcescens ATCC 8100 (MIC 0.25 uM), P-vulgaris ATCC 13315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate
Evidence 30 Activity

Activity

MIC
Antiparasitic
0.25 µM

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

DRAMP

Other

3315 (MIC>80 uM), S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25
Evidence 31 Activity

Activity

MIC
Antiparasitic
1 µM

Target

Enterococcus faecalis ATCC 29212 or VREF clinical isolate

Source & Reference

DRAMP

Other

Cowan 1 MRSA clinical isolate (MIC 0.5-1.0 uM), S. epidermidis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans
Evidence 32 Activity

Activity

MIC
Antiparasitic
0.25 µM

Target

B. megaterium Bm11

Source & Reference

DRAMP

Other

dis ATCC 12228 (MIC 0.25 uM), E. faecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM),
Evidence 33 Activity

Activity

MIC
Antiparasitic
4 µM

Target

Candida albicans clinical isolate

Source & Reference

DRAMP

Other

aecalis ATCC 29212 or VREF clinical isolate (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et
Evidence 34 Activity

Activity

MIC
Antiparasitic
1.0 µM

Target

C. neoformans 3 clinical isolates

Source & Reference

DRAMP

Other

te (MIC 1 uM), B. megaterium Bm11 (MIC 0.25 uM), C. albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC
Evidence 35 Activity

Activity

MIC
Antiparasitic
0.5 µM

Target

R. rubra

Source & Reference

DRAMP

Other

albicans clinical isolate (MIC 4 uM), C. neoformans 3 clinical isolates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2
Evidence 36 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

B. anthracis

Source & Reference

DRAMP

Other

lates (MIC 1.0 uM), and R. rubra (MIC 0.5 uM) ( Skerlavaj et al., 1999 ). It also inhibit B. anthracis (MIC 8 ug/ml) ( Blower et al., 2018 ). Antibiofilm:bacteria: inhibited bacterial biofilm:S. maltophilia
Evidence 37 Activity

Activity

60% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
60% Hemolysis | 100 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Discovery of structural and functional transition sites for membrane-penetrating activity of sheep myeloid antimicrobial peptide-18. | Sci Rep | 2023
Evidence 38 Activity

Activity

50% Hemolysis
Toxicity
23.1 µM
Hemolytic Cytotoxic
50% Hemolysis | 23.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Analogues of peptide SMAP-29 with comparable antimicrobial potency and reduced cytotoxicity. | Int J Antimicrob Agents | 2011
Evidence 39 Activity

Activity

50% Cell death
Toxicity
1.61 µM
Cytotoxic
50% Cell death | 1.61 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Analogues of peptide SMAP-29 with comparable antimicrobial potency and reduced cytotoxicity. | Int J Antimicrob Agents | 2011
Evidence 40 Hemolysis

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.